Cargando…

Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study

BACKGROUND: Whole-exome sequencing has shown that lung adenocarcinoma (LAC) can be driven by mutant genes, including TP53, P16, and Smad4. The aim of this study was to clarify protein alterations of P53, P16, and Smad4 and to explore their correlations between the protein alterations and clinical ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bian, Chunan, Li, Zhongyou, Xu, Youtao, Wang, Jie, Xu, Lin, Shen, Hongbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415338/ https://www.ncbi.nlm.nih.gov/pubmed/25890228 http://dx.doi.org/10.1186/s12957-015-0502-0

Ejemplares similares

Tartrate-Resistant Acid Phosphatase 5/ACP5 Interacts with p53 to Control the Expression of SMAD3 in Lung Adenocarcinoma
por: Hu, Yinan, et al.
Publicado: (2020)

Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis
por: Chou, Cheng-Wei, et al.
Publicado: (2019)

A Novel P53-Related Activity in a Colon Adenocarcinoma Cell Line With Mutant P53
por: Gartel, Andrei L., et al.
Publicado: (2001)

The long non-coding RNA PIK3CD-AS2 promotes lung adenocarcinoma progression via YBX1-mediated suppression of p53 pathway
por: Zheng, Xiufen, et al.
Publicado: (2020)

p16/CDKN2 Gene and p53 Gene Alterations in Japanese Non‐smoking Female Lung Adenocarcinoma
por: Takeshima, Yukio, et al.
Publicado: (1996)

p53’s Extended Reach: The Mutant p53 Secretome
por: Pavlakis, Evangelos, et al.
Publicado: (2020)

A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis
por: Yue, Xuetian, et al.
Publicado: (2016)

Mutant p53 as an Antigen in Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2020)

Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.
por: Gorgoulis, V. G., et al.
Publicado: (1998)

Mutant p53 regulates Survivin to foster lung metastasis
por: Tang, Qiaosi, et al.
Publicado: (2021)

Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53
por: Vikhanskaya, Faina, et al.
Publicado: (2007)

The Correlation Between Mutant p53 Protein Expression and Cell Atypia in Early Differentiated Gastric Adenocarcinoma
por: Tang, Ming, et al.
Publicado: (2021)

p53 tetramerization: at the center of the dominant-negative effect of mutant p53
por: Gencel-Augusto, Jovanka, et al.
Publicado: (2020)

Big bones in p53 mutants
por: LeBrasseur, Nicole
Publicado: (2006)

Mutant p53 succumbs to starvation
por: Moon, Sung-Hwan, et al.
Publicado: (2013)

Chromatin dysregulation by mutant p53
por: Pfister, Neil T., et al.
Publicado: (2016)

Mutant p53 partners in crime
por: Kim, Michael P, et al.
Publicado: (2018)

Mutant p53 in colon cancer
por: Nakayama, Mizuho, et al.
Publicado: (2018)

Mutant p53 in Cancer Progression and Targeted Therapies
por: Zhu, Gaoyang, et al.
Publicado: (2020)

Prognostic value of p16, p53, and pcna in sarcoma and an evaluation of immune infiltration
por: Cai, Dechao, et al.
Publicado: (2022)

Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome
por: Zhang, Yao, et al.
Publicado: (2016)

Editor's Note on ‘Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53’
Publicado: (2023)

p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo
por: Alexandrova, Evguenia M, et al.
Publicado: (2017)

The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells
por: Butera, Giovanna, et al.
Publicado: (2020)

Gain-of-function mutant p53 in cancer progression and therapy
por: Zhang, Cen, et al.
Publicado: (2020)

Identification and validation of a metabolism-related model and associated with tumor-infiltrating lymphocytes in p53 mutant lung adenocarcinoma patients
por: Zheng, Chang, et al.
Publicado: (2021)

LncRNA H19 Promotes Lung Adenocarcinoma Progression via Binding to Mutant p53 R175H
por: Zhou, Yaodong, et al.
Publicado: (2022)

CDK16 Phosphorylates and Degrades p53 to Promote Radioresistance and Predicts Prognosis in Lung Cancer
por: Xie, Jie, et al.
Publicado: (2018)

Smad4 and p53 synergize in suppressing autochthonous intestinal cancer
por: Park, Jun Won, et al.
Publicado: (2022)

FAM111B, a direct target of p53, promotes the malignant process of lung adenocarcinoma
por: Sun, Haijun, et al.
Publicado: (2019)

Correlation between Programmed Death-1 Ligand-1 and p53 in Patients with Lung Adenocarcinoma
por: Xu, Cheng, et al.
Publicado: (2018)

Regulation of Mutant p53 Protein Expression
por: Vijayakumaran, Reshma, et al.
Publicado: (2015)

Targeting mutant p53 for cancer therapy
por: Oren, Moshe, et al.
Publicado: (2016)

SNPing away at mutant p53 activities
por: Ortiz, Guadalupe J., et al.
Publicado: (2018)

Mutant p53 in cell-cell interactions
por: Pilley, Steven, et al.
Publicado: (2021)

Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice
por: Goh, Amanda M., et al.
Publicado: (2015)

The Expression Patterns of p53 and p16 and an Analysis of a Possible Role of HPV in Primary Adenocarcinoma of the Urinary Bladder
por: Alexander, Riley E., et al.
Publicado: (2014)

Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53
por: Ghaleb, Amr, et al.
Publicado: (2019)

Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation
por: Kong, Li Ren, et al.
Publicado: (2020)

Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC
por: Zhang, Yaqun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rf92dig6gqk4gchagojcfc6jtk